Robotic-assisted radical prostatectomy is associated with higher costs than open radical prostatectomy at the index hospitalization for the surgery, but it is associated with less healthcare use during the 1 year after discharge.
This analysis characterizes The National Institutes of Health funding for surgical oncologists.
Surgical delays due to COVID-19 may be safe for some patients with localized RCC, and are unlikely to compromise survival for some individuals.
New data show that complete metastasectomy for selected cases of metastatic renal cell carcinoma (mRCC) prolongs survival in the postcytokine therapy era.
Kidney microstructural features appear predictive of progressive CKD and mortality following radical nephrectomy.
Researchers identified factors for increased risk of clinically significant fatigue among women who underwent surgery for gynecologic cancers.
Experts have developed a new tool for surgical prioritization and ranking for patients with head and neck cancer in a scarce-resource settings associated with the COVID-19 pandemic.
By 2016, radical prostatectomy use nearly equaled radiation therapy use for high-risk prostate cancer.
Investigators highlight the importance of preoperative renal biopsy to rule out an indolent or benign tumor in patients with stage 4 CKD.
A study showed that mortality risk was reduced by 59% for patients who underwent complete metastasectomy compared with those who did not.
